Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMG0703 is a multi-ingredient, film-forming mouthwash developed by **BMG Pharma** for oral care and wound healing applications. The formulation combines **hydrogen peroxide**, **sodium hyaluronate** (hyaluronic acid), and **glycine**. It functions via a dual mechanism: hydrogen peroxide acts as an oxidative antimicrobial agent to reduce bacterial load and control plaque, while sodium hyaluronate forms a protective, hydrating physical barrier over the oral mucosa. This film facilitates tissue regeneration and protects surgical sites or periodontal pockets from external irritation. Glycine is included as a biochemical precursor to support collagen synthesis and accelerated wound repair. BMG0703 is primarily investigated for its efficacy in promoting healing after third molar extractions and in the management of periodontitis by reducing bleeding gums and periodontal pocket depth.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BMG0703.